This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Anoctamin 1 calcium activated chloride channel (ANO1)	<i>In vitro</i> studies suggest compounds that promote ANO1 degradation, as opposed to ANO1 antagonists, could be useful for treating cancer. ANO1 is a critical survival factor for cancer cells. In ANO1-amplified human cancer cell lines, the ANO1 inhibitor CaCC _{inh} -A01 decreased proliferation compared with two other ANO1 inhibitors, a result that suggested functions other than the conductance of ions across ANO1 can affect tumor survival. <i>In vitro</i> studies showed that CaCC _{inh} -A01 decreased ANO1 protein levels by promoting endoplasmic reticulum-associated proteasomal degradation of the protein. Next steps could include developing assays to screen for compounds that promote ANO1 degradation. CaCC _{inh} -A01 is a research compound. SciBX 7(14); doi:10.1038/scibx.2014.394 Published online April 10, 2014	Patent and licensing status unavailable	Bill, A. <i>et al. J. Biol. Chem.</i> ; published online March 5, 2014; doi:10.1074/jbc.M114.549188 Contact: L. Alex Gaither, Novartis Institutes for BioMedical Research, Cambridge, Mass. e-mail: alex.gaither@novartis.com